Hcw Biologics Inc (HCWB)

$3.41 0.00 (N/A)
Market Cap 5.48M
Revenue (ttm) 50,000.00
Net Income (ttm) -7.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15,920.00%
Debt to Equity Ratio 1.14
Volume 51,600
Avg Vol 151,927
Day's Range N/A - N/A
Shares Out 1.60M
Stochastic %K 56%
Beta 2.32
Analysts Strong Sell
Price Target $30.00

Company Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia are...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 842 2024
Fax: 954 842 2037
Address:
2929 North Commerce Parkway, Miramar, United States
TheAlliance
TheAlliance Aug. 7 at 5:49 PM
$YJ $HUIZ $WAFU $HCWB $MB
0 · Reply
TeamBullish
TeamBullish Aug. 7 at 5:32 PM
Plenty of pump and dump, low volume garbage in the market right now amongst the top movers. Not going to throw away gains on low liquidity setups and bad reads. $YJ $HUIZ $WAFU. They could reverse, but I’m good on a Friday after a hot week. Still monitoring $HCWB $MB for any pulse into close.
1 · Reply
Gairbear
Gairbear Aug. 7 at 12:36 PM
$HCWC watching $HCWB
0 · Reply
Donald_J_Dumps
Donald_J_Dumps Aug. 6 at 2:14 AM
$HCWB when this stock becomes more visible this will be the next sls, or delcath. Not often a biotech generates revenue during trials and r&d.
0 · Reply
trekker314
trekker314 Aug. 5 at 5:47 PM
$HCWB What happened? You typically dont drop 10% because, what, someone sneezed. Still holding and bullish.
0 · Reply
Roronao
Roronao Aug. 3 at 11:03 PM
$FBLG $HCWB Win4
0 · Reply
STACKD0E
STACKD0E Aug. 3 at 3:56 PM
$HTCR $HCWB
0 · Reply
Everymoney
Everymoney Aug. 3 at 2:39 PM
$HCWB Volumes are increasing
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 3 at 2:33 PM
$FUSE new high of day $CNCK perking $WLDS former runner $HCWB thin $FCUV consolidating
0 · Reply
BioTerror
BioTerror Aug. 3 at 2:24 PM
$COSM slow and steady ⏳💣 $HCWB $RITR
0 · Reply
Latest News on HCWB
HCW Biologics announces pricing of $1.6M private placement

2026-07-29T13:15:47.000Z - 9 days ago

HCW Biologics announces pricing of $1.6M private placement

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

Jul 29, 2026, 9:06 AM EDT - 9 days ago

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

Jul 23, 2026, 8:00 AM EDT - 15 days ago

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

HCW Biologics regains compliance with Nasdaq

2026-06-30T13:00:59.000Z - 5 weeks ago

HCW Biologics regains compliance with Nasdaq

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

Jun 30, 2026, 8:25 AM EDT - 5 weeks ago

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

Hcw Biologics Inc trading halted, news pending

2026-06-29T23:50:16.000Z - 5 weeks ago

Hcw Biologics Inc trading halted, news pending

HCW Biologics announces 1-for-6 reverse stock split

2026-06-26T13:00:19.000Z - 6 weeks ago

HCW Biologics announces 1-for-6 reverse stock split

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

Jun 26, 2026, 8:55 AM EDT - 6 weeks ago

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

HCW Biologics Registration statement: Registration filing

Jun 18, 2026, 8:00 AM EDT - 7 weeks ago

HCW Biologics Registration statement: Registration filing

HCW Biologics announces data from first two dose cohorts of HCW9302 trial

2026-06-16T11:13:07.000Z - 7 weeks ago

HCW Biologics announces data from first two dose cohorts of HCW9302 trial

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Jun 16, 2026, 7:00 AM EDT - 7 weeks ago

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

HCW Biologics Transcript: AGM 2026

Jun 15, 2026, 10:00 AM EDT - 7 weeks ago

HCW Biologics Transcript: AGM 2026

HCW Biologics registers to sell 5.69M shares of common stock for holders

2026-06-08T14:26:45.000Z - 2 months ago

HCW Biologics registers to sell 5.69M shares of common stock for holders

HCW Biologics Registration statement: Registration filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

HCW Biologics Registration statement: Registration filing

HCW Biologics price target raised to $5 from $2 at Maxim

2026-05-29T12:32:52.000Z - 2 months ago

HCW Biologics price target raised to $5 from $2 at Maxim

HCW Biologics CEO buys $160K in common stock

2026-05-27T23:30:12.000Z - 2 months ago

HCW Biologics CEO buys $160K in common stock

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

May 27, 2026, 7:45 AM EDT - 2 months ago

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

May 22, 2026, 4:02 PM EDT - 2 months ago

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

3 Penny Stocks to Watch Now, 5/21/26

2026-05-21T19:20:55.000Z - 2 months ago

3 Penny Stocks to Watch Now, 5/21/26

MTVA SLXN

HCW Biologics announces pricing of $4M private placement

2026-05-21T14:04:03.000Z - 2 months ago

HCW Biologics announces pricing of $4M private placement

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

May 21, 2026, 9:53 AM EDT - 2 months ago

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

Why Is Penny Stock HCW Biologics (HCWB) Up Today?

2026-05-16T01:04:00.000Z - 2 months ago

Why Is Penny Stock HCW Biologics (HCWB) Up Today?

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

May 14, 2026, 4:25 PM EDT - 3 months ago

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

2026-05-14T14:02:07.000Z - 3 months ago

HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

HCW Biologics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

HCW Biologics Quarterly report: Q1 2026

HCW Biologics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 3 months ago

HCW Biologics Earnings release: Q1 2026

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

May 14, 2026, 7:30 AM EDT - 3 months ago

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Apr 30, 2026, 4:20 PM EDT - 3 months ago

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

HCW Biologics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics to file IND for HCW11-018b in first half of 2027

2026-04-27T13:34:49.000Z - 3 months ago

HCW Biologics to file IND for HCW11-018b in first half of 2027

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors

Apr 27, 2026, 7:30 AM EDT - 3 months ago

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors

HCW Biologics Registration statement: Registration filing

Apr 24, 2026, 8:00 AM EDT - 3 months ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Registration statement: Registration filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

Mar 31, 2026, 5:05 PM EDT - 4 months ago

HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

HCW Biologics Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Annual report: Q4 2025

HCW Biologics Earnings release: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Earnings release: Q4 2025

HCW Biologics Slides: Corporate presentation

Mar 25, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Slides: Corporate presentation

HCW Biologics closes exclusive worldwide license for HCW11-006

2026-03-17T12:00:45.000Z - 5 months ago

HCW Biologics closes exclusive worldwide license for HCW11-006

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

Mar 17, 2026, 7:50 AM EDT - 5 months ago

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

HCW Biologics announces positive research results for CAR-T cell therapy

2026-03-16T12:16:39.000Z - 5 months ago

HCW Biologics announces positive research results for CAR-T cell therapy

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances

Mar 16, 2026, 8:00 AM EDT - 5 months ago

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances

HCW Biologics Proxy statement: Proxy filing

Mar 13, 2026, 8:00 AM EDT - 5 months ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Proxy statement: Proxy filing

Mar 3, 2026, 7:00 AM EST - 5 months ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics regains compliance with continued listing rules for Nasdaq

2026-03-02T13:38:50.000Z - 5 months ago

HCW Biologics regains compliance with continued listing rules for Nasdaq

HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter

Mar 2, 2026, 8:00 AM EST - 5 months ago

HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Feb 17, 2026, 9:50 PM EST - 6 months ago

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Registration statement: Registration filing

Feb 17, 2026, 7:00 AM EST - 6 months ago

HCW Biologics Registration statement: Registration filing

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

Feb 13, 2026, 8:30 AM EST - 6 months ago

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

HCW Biologics Registration statement: Registration filing

Feb 13, 2026, 7:00 AM EST - 6 months ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Registration statement: Registration filing

Feb 11, 2026, 7:00 AM EST - 6 months ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Registration statement: Registration filing

Jan 9, 2026, 7:00 AM EST - 7 months ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

Nov 18, 2025, 7:25 AM EST - 9 months ago

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 14, 2025, 4:44 PM EST - 9 months ago

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

HCW Biologics Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

HCW Biologics Quarterly report: Q3 2025

HCW Biologics Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

HCW Biologics Earnings release: Q3 2025

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 7, 2025, 7:00 AM EST - 9 months ago

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

HCW Biologics to Participate in the 2025 Maxim Growth Summit

Oct 16, 2025, 9:25 AM EDT - 10 months ago

HCW Biologics to Participate in the 2025 Maxim Growth Summit

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Sep 30, 2025, 8:45 AM EDT - 11 months ago

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Sep 18, 2025, 9:15 AM EDT - 11 months ago

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Sep 16, 2025, 8:00 AM EDT - 11 months ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Aug 25, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 18, 2025, 2:44 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

HCW Biologics Quarterly report: Q2 2025

Aug 18, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Quarterly report: Q2 2025

HCW Biologics Earnings release: Q2 2025

Aug 18, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Earnings release: Q2 2025

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Jun 27, 2025, 7:45 AM EDT - 1 year ago

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

Jun 26, 2025, 7:55 AM EDT - 1 year ago

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

Jun 4, 2025, 8:20 AM EDT - 1 year ago

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

May 15, 2025, 6:14 PM EDT - 1 year ago

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

HCW Biologics Quarterly report: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Quarterly report: Q1 2025

HCW Biologics Earnings release: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Earnings release: Q1 2025

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

May 13, 2025, 8:01 PM EDT - 1 year ago

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

May 13, 2025, 8:30 AM EDT - 1 year ago

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

HCW Biologics Registration statement: Registration filing

May 13, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Registration statement: Registration filing

May 9, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Proxy statement: Proxy filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Proxy statement: Proxy filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Registration statement: Registration filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Registration statement: Registration filing

HCW Biologics Announces 1-for-40 Reverse Stock Split

Apr 1, 2025, 4:35 PM EDT - 1 year ago

HCW Biologics Announces 1-for-40 Reverse Stock Split

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Mar 28, 2025, 3:30 PM EDT - 1 year ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

HCW Biologics Annual report: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Annual report: Q4 2024

HCW Biologics Earnings release: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Earnings release: Q4 2024

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

Mar 6, 2025, 6:55 AM EST - 1 year ago

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

HCW Biologics Proxy statement: Proxy filing

Feb 26, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Proxy statement: Proxy filing

Feb 21, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Proxy statement: Proxy filing

Feb 11, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Feb 3, 2025, 7:15 AM EST - 1 year ago

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

HCW Biologics Transcript: AGM 2025

Jan 17, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Transcript: AGM 2025

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Jan 15, 2025, 7:00 AM EST - 1 year ago

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Dec 23, 2024, 8:10 AM EST - 1 year ago

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Nov 18, 2024, 9:27 PM EST - 1 year ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

Nov 18, 2024, 7:00 AM EST - 1 year ago

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 14, 2024, 4:40 PM EST - 1 year ago

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

HCW Biologics Quarterly report: Q3 2024

HCW Biologics Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

HCW Biologics Earnings release: Q3 2024

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Aug 23, 2024, 4:30 PM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 14, 2024, 4:35 PM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Quarterly report: Q2 2024

HCW Biologics Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Earnings release: Q2 2024

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

May 15, 2024, 4:39 PM EDT - 2 years ago

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Quarterly report: Q1 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Quarterly report: Q1 2024

HCW Biologics Earnings release: Q1 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Earnings release: Q1 2024

HCW Biologics Proxy statement: Proxy filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Proxy statement: Proxy filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Proxy statement: Proxy filing

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Apr 1, 2024, 4:10 PM EDT - 2 years ago

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Annual report: Q4 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Annual report: Q4 2023

HCW Biologics Earnings release: Q4 2023

Apr 1, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Earnings release: Q4 2023

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

Nov 14, 2023, 7:00 AM EST - 2 years ago

HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights

HCW Biologics Quarterly report: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

HCW Biologics Quarterly report: Q3 2023

HCW Biologics Earnings release: Q3 2023

Nov 14, 2023, 7:00 AM EST - 2 years ago

HCW Biologics Earnings release: Q3 2023

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Nov 8, 2023, 7:30 AM EST - 2 years ago

Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 3 years ago

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Sep 6, 2023, 7:30 AM EDT - 3 years ago

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

TheAlliance
TheAlliance Aug. 7 at 5:49 PM
$YJ $HUIZ $WAFU $HCWB $MB
0 · Reply
TeamBullish
TeamBullish Aug. 7 at 5:32 PM
Plenty of pump and dump, low volume garbage in the market right now amongst the top movers. Not going to throw away gains on low liquidity setups and bad reads. $YJ $HUIZ $WAFU. They could reverse, but I’m good on a Friday after a hot week. Still monitoring $HCWB $MB for any pulse into close.
1 · Reply
Gairbear
Gairbear Aug. 7 at 12:36 PM
$HCWC watching $HCWB
0 · Reply
Donald_J_Dumps
Donald_J_Dumps Aug. 6 at 2:14 AM
$HCWB when this stock becomes more visible this will be the next sls, or delcath. Not often a biotech generates revenue during trials and r&d.
0 · Reply
trekker314
trekker314 Aug. 5 at 5:47 PM
$HCWB What happened? You typically dont drop 10% because, what, someone sneezed. Still holding and bullish.
0 · Reply
Roronao
Roronao Aug. 3 at 11:03 PM
$FBLG $HCWB Win4
0 · Reply
STACKD0E
STACKD0E Aug. 3 at 3:56 PM
$HTCR $HCWB
0 · Reply
Everymoney
Everymoney Aug. 3 at 2:39 PM
$HCWB Volumes are increasing
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 3 at 2:33 PM
$FUSE new high of day $CNCK perking $WLDS former runner $HCWB thin $FCUV consolidating
0 · Reply
BioTerror
BioTerror Aug. 3 at 2:24 PM
$COSM slow and steady ⏳💣 $HCWB $RITR
0 · Reply
BioTerror
BioTerror Aug. 3 at 2:13 PM
$RITR monster 😤 also $HCWB
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Aug. 3 at 2:13 PM
$HCWB Needs volume
0 · Reply
vcaelum
vcaelum Aug. 3 at 2:05 PM
$HCWB I'm in 4.2 HARD SL 3.6
0 · Reply
ahTony
ahTony Aug. 3 at 10:11 AM
$HCWB nice weekly chart and bullish news.
0 · Reply
ahTony
ahTony Aug. 3 at 10:01 AM
$HCWB microflaot swing candidate. 📢 3.30.
0 · Reply
TD281
TD281 Aug. 1 at 5:51 PM
$HCWB Ceo load up shares prior to incoming news.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 31 at 10:15 PM
$HCWB CEO purchased 23,210 shares at $2.58 for a total of $59,998. Wong Hing C now owns 125,845 shares. https://ceo-buys.com
0 · Reply
TD281
TD281 Jul. 31 at 8:40 PM
$HCWB HCW Biologics director Scott T. Garrett acquires 7,736 common shares for $19,995.56
0 · Reply
trader87
trader87 Jul. 30 at 4:47 PM
$HCWB reversal in progress,swing is still on, pt lowered to 6.50
1 · Reply
Tub66516
Tub66516 Jul. 29 at 1:51 PM
$HCWB
1 · Reply